Sign in
Not yet taking people in FrancePhase 3

Metyrapone for mild cortisol excess in adrenal gland enlargement (PBMAH)

Tests metyrapone in people with PBMAH and mild Cushing syndrome.

Key facts

Who runs it
Assistance Publique Hopitaux De Paris
Where
Boulogne-Billancourt, Bron, Grenoble Cedex 09, Lille Cedex, Marseille, Paris, Pessac, Rouen, Saint-Herblain, Toulouse, and Vandoeuvre Les Nancy, FranceSee the 11 sites
Registry title
CUSHMAH - Benefit of steroidogenesis inhibitors in Mild Cushing syndrome (Mild Autonomous Cortisol Secretion): a randomized trial in patients with Primary Bilateral Macronodular Adrenocortical Hyperplasia
Status
Not yet recruiting
Phase
Phase 3
People taking part
70 people, planned
Started
1 Sept 2026
Expected to end
1 Jul 2030
Type of study
Interventional
Record updated
5 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with PBMAH (many nodules in both adrenal glands) and mild cortisol excess, who also have high blood pressure and/or diabetes. It tests whether metyrapone, which lowers cortisol, improves them.

Age
18 years and older
Sex
All sexes
Disease stage
PBMAH seen on CT-scan and/or MRI, with several nodules in both adrenal glands. Mild autonomous cortisol secretion: plasma cortisol after 1 mg overnight dexamethasone test > 50 nmol/L, and 24 h urinary free cortisol < 1,5 upper limit of normal. Cortisol excess comes from the adrenal glands. People must also have high blood pressure (above 140 or 90 mmHg) or treated high blood pressure, and/or diabetes that can be treated with medicines.
Earlier treatment
No steroidogenesis inhibitor treatment in the 6 weeks before joining. No glucocorticoid treatment (systemic or high dose local).
Biomarker or test result
Morning plasma ACTH < 10 pg/ml, or between 10 and 20 pg/ml with no response to CRH stimulation (stimulation < 50 %).

Main reasons for not taking part

  • Cushing syndrome from a cause other than PBMAH
  • Pregnant or breastfeeding women
  • Uncontrolled diabetes (HBA1c > 9 % (75 mmol/mol))
  • QT/QTc interval > 470ms (women) or > 450ms (men), or drugs that can prolong QT
  • Proven primary adrenal insufficiency, or an illness likely to be fatal within 1 year

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • Age ≥ 18 years old
  • French speaking
  • Patient with PBMAH as determined by adrenal imaging (CT-scan and/or MRI) showing multiples bilateral supracentrimetric adrenal nodules
  • Mild autonomous cortisol secretion: plasma cortisol after 1 mg overnight dexamethasone test > 50 nmol/L, 24 h Urinary free cortisol < 1,5 upper limit of Normal
  • Adrenal origin of cortisol excess: morning plasma ACTH < 10 pg/ml or between 10 and 20 pg/ml non responsive to CRH stimulation (stimulation < 50 %)
  • Hypertension (systolic blood pressure > 140 mmHg or diastolic blood pressure > 90 mmHg) or treated hypertension and/or diabetes that can be treated with antidiabetic treatments (WHO criteria)
  • For women of childbearing potential (WOCBP), negative bHCG and highly effective contraception
  • For male, an effective method of contraception
  • Signed a written informed consent
  • Affiliated to social security regime or an equivalent system

Who cannot take part

  • Steroidogenesis inhibitor treatment less than 6 weeks before inclusion
  • Contraindication to steroidogenesis inhibitor
  • Patients with a Cushing syndrome from another causes than PBMAH
  • Patients with major psychiatric disorders that may interfere with the smooth running of the study
  • Patients with proven primary adrenal insufficiency
  • Hypersensitivity to the active substance or to one of its excipients
  • Uncontrolled diabetes (HBA1c > 9 %)
  • Patients at high risk of cardiac rhythm disorders with QT/QTc interval > 470ms (for women) and > 450ms (for men)
  • Drugs with a known risk of QT prolongation as listed in https://crediblemeds.org
  • Pregnancy or breastfeeding women
  • Pathology that is life-threatening in the short term (1 year)
  • Patients on AME (state medical aid)
  • Participation to another clinical trial on medicinal products for human use
  • Under glucocorticoid (systemic or high dose local) treatment
  • Loop diuretics and thiazide or thiazide-like diuretic that can cause hypokaliemia

Where in France

  • Assistance Publique Hopitaux De ParisBoulogne-Billancourt, FranceNot yet recruiting
  • Hospices Civils de LyonBron, FranceNot yet recruiting
  • Centre Hospitalier Universitaire Grenoble AlpesGrenoble Cedex 09, FranceNot yet recruiting
  • Centre Hospitalier Universitaire De LilleLille Cedex, FranceNot yet recruiting
  • Centre Hospitalier Regional De MarseilleMarseille, FranceNot yet recruiting
  • Assistance Publique Hopitaux de ParisParis, FranceNot yet recruiting
  • Centre Hospitalier Universitaire de BordeauxPessac, FranceNot yet recruiting
  • Centre Hospitalier Universitaire RouenRouen, FranceNot yet recruiting
  • Centre Hospitalier Universitaire de NantesSaint-Herblain, FranceNot yet recruiting
  • Centre Hospitalier Universitaire de ToulouseToulouse, FranceNot yet recruiting
  • CHRU De NancyVandoeuvre Les Nancy, FranceNot yet recruiting

About the trial

What the trial wants to find out

Demonstrate that cortisol secretion inhibition by medical treatment (metyrapone) in PBMAH patients with MACS lead to improvement of hypertension and diabetes.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
CUSHMAH - Benefit of steroidogenesis inhibitors in Mild Cushing syndrome (Mild Autonomous Cortisol Secretion): a randomized trial in patients with Primary Bilateral Macronodular Adrenocortical Hyperplasia
Plain-language title
Metyrapone for mild cortisol excess in adrenal gland enlargement (PBMAH)Generated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
5 March 2026